lorlatinib

Overview

Lorlatinib is a third-generation macrocyclic ALK/ROS1 tyrosine kinase inhibitor designed to overcome resistance mutations (including G1202R) that limit first- and second-generation ALK inhibitors. It has superior CNS penetration compared with earlier-generation agents. Lorlatinib is approved for first-line treatment of ALK-positive NSCLC (CROWN trial) and for patients who have progressed on prior ALK TKIs.

Evidence in the corpus

• ALK/ROS1-targeted therapy for ALK rearrangements over-represented in young-onset NSCLC; CROWN trial subgroup analyses showed consistent outcomes across age subgroups; review notes ALK TKIs (including lorlatinib) are not covered by Indian public healthcare schemes PMID:27346245

Resistance mechanisms

Cancer types (linked)

• NSCLC
• LUAD

Sources

This page was processed by crosslinker on 2026-05-14.